![Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase | British Journal of Cancer Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2015.8/MediaObjects/41416_2015_Article_BFbjc20158_Fig1_HTML.jpg)
Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase | British Journal of Cancer
![The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer | Breast Cancer Management The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer | Breast Cancer Management](https://www.futuremedicine.com/cms/10.2217/bmt-2020-0015/asset/images/medium/figure1.gif)
The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer | Breast Cancer Management
The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study | PLOS Medicine
![Ca-125 in Ovarian Cancer: To Test or Not to Test? – Latest and Best Treatments in Oncology & Radiotherapy Ca-125 in Ovarian Cancer: To Test or Not to Test? – Latest and Best Treatments in Oncology & Radiotherapy](https://drbhnglatest.files.wordpress.com/2017/09/screen-shot-2018-06-11-at-10-05-53-pm.png?w=1108)
Ca-125 in Ovarian Cancer: To Test or Not to Test? – Latest and Best Treatments in Oncology & Radiotherapy
![PDF] REVIEW OF CARCINOMA ANTIGEN 125 (CA 125) AS A MARKER OF DISEASE PROGRESSION OR RECURRENCE IN CLINICAL TRIALS | Semantic Scholar PDF] REVIEW OF CARCINOMA ANTIGEN 125 (CA 125) AS A MARKER OF DISEASE PROGRESSION OR RECURRENCE IN CLINICAL TRIALS | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a41774d54ed2429de098b01664d00db2774149da/6-Figure2-1.png)
PDF] REVIEW OF CARCINOMA ANTIGEN 125 (CA 125) AS A MARKER OF DISEASE PROGRESSION OR RECURRENCE IN CLINICAL TRIALS | Semantic Scholar
![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.va.gif)
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.tbl1.png)